While the Dandelion algorithm is able to combine measures from medication orders to assess the estimated duration of treatment as prescribed by a physician, we cannot speak to the downstream behavior at the patient level
The FDA's overview of GLP-1 medications also highlights the importance of using these medications under appropriate medical supervision
In the SUSTAIN trial, 52% of patients receiving semaglutide experienc ed gastrointestinal side effects, compared with 35% in the placebo group
$14,000 to $18,000 annually $8,000 to $12,000 annually $4,000 to $7,000 annually $1,500 to $3,500 annually The substantial difference between retail and research peptide pricing makes long term treatment accessible for many Canadians who could not otherwise afford it